JP2023514452A5 - - Google Patents

Info

Publication number
JP2023514452A5
JP2023514452A5 JP2022550908A JP2022550908A JP2023514452A5 JP 2023514452 A5 JP2023514452 A5 JP 2023514452A5 JP 2022550908 A JP2022550908 A JP 2022550908A JP 2022550908 A JP2022550908 A JP 2022550908A JP 2023514452 A5 JP2023514452 A5 JP 2023514452A5
Authority
JP
Japan
Prior art keywords
binding
cov
scaffold
sars
spike protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2022550908A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023514452A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/019739 external-priority patent/WO2021173879A1/en
Publication of JP2023514452A publication Critical patent/JP2023514452A/ja
Publication of JP2023514452A5 publication Critical patent/JP2023514452A5/ja
Withdrawn legal-status Critical Current

Links

JP2022550908A 2020-02-25 2021-02-25 生体模倣ウイルスペプチドの特定及びその使用 Withdrawn JP2023514452A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202062981453P 2020-02-25 2020-02-25
US62/981,453 2020-02-25
US202063002249P 2020-03-30 2020-03-30
US63/002,249 2020-03-30
US202062706225P 2020-08-05 2020-08-05
US62/706,225 2020-08-05
US202063091291P 2020-10-13 2020-10-13
US63/091,291 2020-10-13
PCT/US2021/019739 WO2021173879A1 (en) 2020-02-25 2021-02-25 Identification of biomimetic viral peptides and uses thereof

Publications (2)

Publication Number Publication Date
JP2023514452A JP2023514452A (ja) 2023-04-05
JP2023514452A5 true JP2023514452A5 (cg-RX-API-DMAC7.html) 2024-03-05

Family

ID=77492020

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022550908A Withdrawn JP2023514452A (ja) 2020-02-25 2021-02-25 生体模倣ウイルスペプチドの特定及びその使用

Country Status (9)

Country Link
US (1) US20230242592A1 (cg-RX-API-DMAC7.html)
EP (1) EP4110366A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023514452A (cg-RX-API-DMAC7.html)
KR (1) KR20220158723A (cg-RX-API-DMAC7.html)
CN (1) CN115461068A (cg-RX-API-DMAC7.html)
AU (1) AU2021227918A1 (cg-RX-API-DMAC7.html)
CA (1) CA3172878A1 (cg-RX-API-DMAC7.html)
IL (1) IL295863A (cg-RX-API-DMAC7.html)
WO (1) WO2021173879A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20220552A (es) 2020-04-02 2023-01-17 Regeneron Pharma Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno
JP7854660B2 (ja) 2020-05-22 2026-05-07 国立研究開発法人理化学研究所 コロナウイルスに対する多重抗原ペプチドおよびこれを含む免疫賦活化組成物
MX2022014598A (es) 2020-05-26 2023-03-31 Regeneron Pharma Anticuerpos anti-glicoproteína espicular sars-cov-2 y fragmentos de unión al antígeno.
CR20220660A (es) 2020-06-03 2023-02-17 Regeneron Pharma Métodos para tratar o prevenir infecciones por sars-cov2 y covid-19 con anticuerpos de glicoproteína espícular anti-sars-cov-2
EP4370210A1 (en) 2021-07-14 2024-05-22 Regeneron Pharmaceuticals, Inc. Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
EP4396204A4 (en) 2021-09-17 2025-11-12 David Kotlyar Oral vaccine via dental bacteria and peptides released to prevent COVID-19 infection
IT202200025416A1 (it) * 2022-12-13 2024-06-13 Univ Pisa Biosensore per la rilevazione di particelle virali
CN117153245B (zh) * 2023-10-18 2024-03-19 无锡市疾病预防控制中心 预测新型冠状病毒S蛋白RBD区域与hACE2受体相互作用的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101080237A (zh) * 2003-04-28 2007-11-28 塞阔伊亚药品公司 用于治疗、控制和预防冠状病毒感染的抗病毒剂
CN1884303A (zh) * 2005-06-20 2006-12-27 中国医学科学院基础医学研究所 SARS-CoV病毒结构蛋白的融合蛋白及其高量表达与纯化和用途
WO2017046801A1 (en) * 2015-09-17 2017-03-23 Ramot At Tel-Aviv University Ltd. Coronaviruses epitope-based vaccines
RU2019121801A (ru) * 2016-12-14 2021-01-15 Лигандал, Инк. Композиции и способы для доставки полезной нагрузки в виде нуклеиновой кислоты и/или белка
US11365239B2 (en) * 2020-03-20 2022-06-21 Tsb Therapeutics (Beijing) Co., Ltd. Anti-SARS-COV-2 antibodies and uses thereof

Similar Documents

Publication Publication Date Title
ES2742739T3 (es) Proteínas de fusión para uso como mejoradores inmunogénicos para inducir respuestas de células T específicas de antígenos
ES2258796T3 (es) Proteinas de fusion que contienen proteinas de estres para inducir respuestas inmunitarias.
JP2022533318A5 (cg-RX-API-DMAC7.html)
US9943583B2 (en) Proline-rich peptides protective against S. pneumoniae
JP2024522385A5 (cg-RX-API-DMAC7.html)
JP2020169191A5 (cg-RX-API-DMAC7.html)
AU2013250711A1 (en) Long-acting oxyntomodulin variants and methods of producing same
JP2008535800A5 (cg-RX-API-DMAC7.html)
JP2008504012A5 (cg-RX-API-DMAC7.html)
JP2011518179A5 (cg-RX-API-DMAC7.html)
JP2015536134A5 (cg-RX-API-DMAC7.html)
CN113453703A (zh) 包括胰岛素和对胰高血糖素和glp-1和gip受体均具有活性的三重激动剂的药物组合物
CN113260377B (zh) 脂肽构建块和合成病毒样颗粒
CN111655284A (zh) 流感病毒疫苗及其用途
CN105229025A (zh) 位点特异性胰岛素缀合物
CN113769080B (zh) 多肽免疫偶联物及其应用
JP4199421B2 (ja) デキストラン−レプチン結合体、医薬組成物および関連方法
WO2008154867A1 (fr) Composé immunogénique
JP2012521207A5 (cg-RX-API-DMAC7.html)
KR20200136774A (ko) Rsv의 f 단백질-항체 복합체 및 이를 포함하는 조성물
JP2025519475A5 (cg-RX-API-DMAC7.html)
EP1001978B1 (en) Angiotensin derivatives
BR112019026336A2 (pt) forma de sal de cloridrato de um peptídeo análogo da porção c-terminal de c5a e o uso da mesma, composição, método para induzir uma resposta imune contra uma infecção ou câncer, kit e composto para aumentar uma resposta imune para um agente imunogênico
JP2023534987A5 (cg-RX-API-DMAC7.html)
RU2014117975A (ru) Гибридные белки и белковые конъюгаты на основе белков теплового шока-70 (бтш70) и способы их применения (варианты)